Drugs / [F-18] FMISO
[F-18] FMISO
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01213030 Comparator | Jun 2009 → Jan 2010 | head and neck cancer, liver cancer, lung cancer | Siemens Molecular Imaging | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18] FMISO | “Drug: [F-18] FMISO” NCT01213030 ↗ |
| Known as | fluorine-18 fluoromisonidazole | “Positron Emission Tomography (PET) with fluorine-18 fluoromisonidazole (FMISO) has been used for several years as a non invasive imaging technique to study tumor hypoxia.” NCT01213030 ↗ |
| Known as | FMISO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01213030 ↗ |
| Modality | Diagnostic / imaging agent | “Positron Emission Tomography (PET) with fluorine-18 fluoromisonidazole (FMISO) has been used for several years as a non invasive imaging technique to study tumor hypoxia.” NCT01213030 ↗ |